nach oben

Immunologic Research

Erschienen in:

14.11.2017 | Original Article

CD28^neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs

verfasst von: Hisayoshi Hashimoto, Marco Sterk, Karin Schilbach

Erschienen in: Immunologic Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Increased numbers of CD8⁺CD28^neg. T cells have been detected in the peripheral blood of patients with several types of malignancies. However, the role of these cells in anticancer immunity are not yet clear and CD8⁺CD28^neg. T cells are a controversially discussed subpopulation reported both as immunosuppressive and cytotoxic. In this study, we examined the T cell receptor (TCR) repertoire and complementarity-determining region 3 sequences of CD28^neg. T cells in a melanoma patient with recurrent disease who achieved long-term disease-free status. As a result, the patient’s oligoclonal CD8⁺CD28^neg. T cell compartment holds TCRs that are public and specific for Melan-A as well as several public TCRs reported for common viral antigens. While over 80% of his CD8⁺CD28^neg. T cells expressed a cytotoxicity marker, CD57, only 0.01% of CD8⁺ CD28^neg. T cells were positive for Foxp3. In conclusion, our results demonstrate that besides virus-specific also tumor-associated self-antigen targeting T cells accumulate in the CD28^neg. compartment of the immunological memory. Since the patient is in ongoing complete remission for more than 9 years, CD8⁺CD28^neg. T cells with the Melan-A-specific TCR might contribute to antitumor immunity in this patient.

Dumitriu IE. The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases. Immunology. 2015;146(2):185–93. https://doi.org/10.1111/imm.12506.CrossRefPubMedPubMedCentral

Maly K, Schirmer M. Corrigendum to “The story of CD4 (⁺) CD28(⁻) T cells revisited: solved or still ongoing?”. J Immunol Res. 2015;2015:251657. https://doi.org/10.1155/2015/251657.PubMedPubMedCentral

Weng NP, Akbar AN, Goronzy J. CD28(⁻) T cells: their role in the age-associated decline of immune function. Trends Immunol. 2009;30(7):306–12. https://doi.org/10.1016/j.it.2009.03.013.CrossRefPubMedPubMedCentral

Mou D, Espinosa J, Lo DJ, Kirk AD. CD28 negative T cells: is their loss our gain? Am J Transplant. 2014;14(11):2460–6. https://doi.org/10.1111/ajt.12937.CrossRefPubMedPubMedCentral

Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134(1):17–32. https://doi.org/10.1111/j.1365-2567.2011.03470.x.CrossRefPubMedPubMedCentral

Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. Antigenic and functional properties. J Immunol. 1993;150(4):1147–59.PubMed

Ciubotariu R, Colovai AI, Pennesi G, Liu Z, Smith D, Berlocco P, et al. Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol. 1998;161(10):5193–202.PubMed

Casado JG, Soto R, DelaRosa O, Peralbo E, Muñoz-Villanueva MC, Rioja L, et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother. 2005;54(12):1162–71. https://doi.org/10.1007/s00262-005-0682-5.CrossRefPubMed

Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol. 2007;179(7):4323–34. https://doi.org/10.4049/jimmunol.179.7.4323.CrossRefPubMed

10.

Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol. 2006;67(1–2):1–12. https://doi.org/10.1016/j.humimm.2005.11.005.CrossRefPubMed

11.

Ye SW, et al. Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. J Clin Immunol. 2006;26(5):447–56. https://doi.org/10.1007/s10875-006-9040-4.CrossRefPubMed

12.

Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, et al. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 integrin) in high-grade serous ovarian cancer. Gynecol Oncol. 2010;118(3):228–36. https://doi.org/10.1016/j.ygyno.2010.05.016.CrossRefPubMed

13.

Urbaniak-Kujda D, Kapelko-Słowik K, Wołowiec D, Dybko J, Hałoń A, Jaźwiec B, et al. Increased percentage of CD8+CD28- suppressor lymphocytes in peripheral blood and skin infiltrates correlates with advanced disease in patients with cutaneous T-cell lymphomas. Postepy Hig Med Dosw (Online). 2009;63:355–9.

14.

Gruber IV, el Yousfi S, Dürr-Störzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 2008;28(2a):779–84.PubMed

15.

Schule JM, et al. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J Transl Med. 2004;2(1):45. https://doi.org/10.1186/1479-5876-2-45.CrossRefPubMedPubMedCentral

16.

Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, et al. Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology. 2015;4(7):e1014760. https://doi.org/10.1080/2162402X.2015.1014760.CrossRefPubMedPubMedCentral

17.

Fagnoni FF, et al. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology. 1996;88(4):501–7. https://doi.org/10.1046/j.1365-2567.1996.d01-689.x.CrossRefPubMedPubMedCentral

18.

Fasth AE, et al. CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol. 2004;60(1–2):199–208. https://doi.org/10.1111/j.0300-9475.2004.01464.x.CrossRefPubMed

19.

Trautmann L, Labarrière N, Jotereau F, Karanikas V, Gervois N, Connerotte T, et al. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol. 2002;32(11):3181–90. https://doi.org/10.1002/1521-4141(200211)32:11<3181::AID-IMMU3181>3.0.CO;2-2.CrossRefPubMed

20.

Bourcier KD, Lim DG, Ding YH, Smith KJ, Wucherpfennig K, Hafler DA. Conserved CDR3 regions in T-cell receptor (TCR) CD8(+) T cells that recognize the Tax11-19/HLA-A*0201 complex in a subject infected with human T-cell leukemia virus type 1: relationship of T-cell fine specificity and major histocompatibility complex/peptide/TCR crystal structure. J Virol. 2001;75(20):9836–43. https://doi.org/10.1128/JVI.75.20.9836-9843.2001.CrossRefPubMedPubMedCentral

21.

Campos-Lima PO, Levitsky V, Imreh MP, Gavioli R, Masucci MG. Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med. 1997;186(1):83–9. https://doi.org/10.1084/jem.186.1.83.CrossRefPubMedPubMedCentral

22.

Moss PA, Moots RJ, Rosenberg WM, Rowland-Jones SJ, Bodmer HC, McMichael AJ, et al. Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci U S A. 1991;88(20):8987–90. https://doi.org/10.1073/pnas.88.20.8987.CrossRefPubMedPubMedCentral

23.

Miles JJ, Thammanichanond D, Moneer S, Nivarthi UK, Kjer-Nielsen L, Tracy SL, et al. Antigen-driven patterns of TCR bias are shared across diverse outcomes of human hepatitis C virus infection. J Immunol. 2011;186(2):901–12. https://doi.org/10.4049/jimmunol.1003167.CrossRefPubMed

24.

Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013;19(9):1680–98.PubMedPubMedCentral

25.

Barbon CM, Davies JK, Voskertchian A, Kelner RH, Brennan LL, Nadler LM, et al. Alloanergization of human T cells results in expansion of alloantigen-specific CD8(⁺) CD28(⁻) suppressor cells. Am J Transplant. 2014;14(2):305–18. https://doi.org/10.1111/ajt.12575.CrossRefPubMed

26.

Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol. 2004;16(8):1055–68. https://doi.org/10.1093/intimm/dxh107.CrossRefPubMed

27.

Focosi D, Bestagno M, Burrone O, Petrini M. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol. 2010;87(1):107–16. https://doi.org/10.1189/jlb.0809566.CrossRefPubMed

28.

Mantovani S, Palermo B, Garbelli S, Campanelli R, Robustelli della Cuna G, Gennari R, et al. Dominant TCR-alpha requirements for a self antigen recognition in humans. J Immunol. 2002;169(11):6253–60. https://doi.org/10.4049/jimmunol.169.11.6253.CrossRefPubMed

29.

Dietrich PY, le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, et al. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol. 2003;170(10):5103–9. https://doi.org/10.4049/jimmunol.170.10.5103.CrossRefPubMed

30.

Dutoit V, Rubio-Godoy V, Pittet MJ, Zippelius A, Dietrich PY, Legal FA, et al. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-A peptide multimer(+) CD8(+) T cells in humans. J Exp Med. 2002;196(2):207–16. https://doi.org/10.1084/jem.20020242.CrossRefPubMedPubMedCentral

31.

Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190(5):705–15. https://doi.org/10.1084/jem.190.5.705.CrossRefPubMedPubMedCentral

32.

Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med. 2002;195(4):485–94. https://doi.org/10.1084/jem.20011658.CrossRefPubMedPubMedCentral

33.

Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol. 2006;6(12):883–94. https://doi.org/10.1038/nri1977.CrossRefPubMed

34.

Weekes MP, Wills MR, Mynard K, Hicks R, Sissons JGP, Carmichael AJ. Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population. Immunology. 1999;98(3):443–9. https://doi.org/10.1046/j.1365-2567.1999.00901.x.CrossRefPubMedPubMedCentral

35.

Weekes MP, Carmichael AJ, Wills MR, Mynard K, Sissons JG. Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol. 1999;162(12):7569–77.PubMed

36.

Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol. 2008;26(1):171–203. https://doi.org/10.1146/annurev.immunol.26.021607.090421.CrossRefPubMedPubMedCentral

37.

Weinberger B, Welzl K, Herndler-Brandstetter D, Parson W, Grubeck-Loebenstein B. CD28(−)CD8(+) T cells do not contain unique clonotypes and are therefore dispensable. Immunol Lett. 2009;127(1):27–32. https://doi.org/10.1016/j.imlet.2009.08.008.CrossRefPubMed

38.

Hirokawa M, Horiuchi T, Kawabata Y, Kitabayashi A, Saitoh H, Ichikawa Y, et al. Oligoclonal expansion of CD4(+)CD28(−) T lymphocytes in recipients of allogeneic hematopoietic cell grafts and identification of the same T cell clones within both CD4(+)CD28(+) and CD4(+)CD28(−) T cell subsets. Bone Marrow Transplant. 2001;27(10):1095–100. https://doi.org/10.1038/sj.bmt.1703045.CrossRefPubMed

39.

Horiuchi T, Hirokawa M, Kawabata Y, Kitabayashi A, Matsutani T, Yoshioka T, et al. Identification of the T cell clones expanding within both CD8(+)CD28(+) and CD8(+)CD28(−) T cell subsets in recipients of allogeneic hematopoietic cell grafts and its implication in post-transplant skewing of T cell receptor repertoire. Bone Marrow Transplant. 2001;27(7):731–9. https://doi.org/10.1038/sj.bmt.1702859.CrossRefPubMed

Titel: CD28neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs
verfasst von: Hisayoshi Hashimoto
Marco Sterk
Karin Schilbach
Publikationsdatum: 14.11.2017
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 1/2018
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-017-8976-1

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

CD28^neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians

Th2-biased immune response and agglutinating antibodies generation by a chimeric protein comprising OmpC epitope (323–336) of Aeromonas hydrophila and LTB

IL-2 mediates NK cell proliferation but not hyperactivity

Dual neutralization of TNFR-2 and MMP-2 regulates the severity of S. aureus induced septic arthritis correlating alteration in the level of interferon gamma and interleukin-10 in terms of TNFR2 blocking

Human amylin induces CD4+Foxp3+ regulatory T cells in the protection from autoimmune diabetes

FGL2 knockdown improves heart function through regulation of TLR9 signaling in the experimental autoimmune myocarditis rats

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO